Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

European stocks rise as AstraZeneca gains on UK vaccine approval

Published 12/30/2020, 03:26 AM
Updated 12/30/2020, 07:32 AM
© Reuters. The German share price index DAX graph is pictured at the stock exchange in Frankfurt

By Sruthi Shankar

(Reuters) -European stocks inched higher on Wednesday as UK's approval of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, bets of more U.S. fiscal aid and large-scale vaccination efforts spurred hopes of a strong recovery in the global economy next year.

The pan-European STOXX 600 rose 0.2% to hover near a 10-month high hit in the previous session.

German DAX slipped ahead of an early close on Wednesday, with most markets in the region being subdued due to thin volumes in the final week of the year.

AstraZeneca rose 0.8% after Britain became the first country in the world to approve its vaccine jointly developed with Oxford University.

That came as an additional boost for UK markets after Britain and EU sealed a Brexit trade deal last week, averting a chaotic departure from the bloc at the end of year. The British parliament is expected to debate and pass the deal later in the day.

HSBC, Lloyds Banking Group (LON:LLOY) and Barclays (LON:BARC) rose almost 2%, boosting UK's blue-chip FTSE 100, which rose 0.3%.

Meanwhile, Wall Street indexes hit all-time highs this week on hopes that U.S. lawmakers will approve a large fiscal stimulus package despite delays.

"There are some things happening out there that suggests that risk appetite is strong," said Russ Mould, investment director at AJ Bell.

"If you're looking through to 2021, we're hoping that the vaccines will begin to counteract the effect of the pandemic, and hopefully economic activity will begin to normalise."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Spanish lender Unicaja rose 2.7%, while Liberbank was down 3.1%, after they announced an all-in share deal that would create the country's fifth-biggest bank.

The deal marks an acceleration of the sector's consolidation after the approval of a merger between state-owned Bankia and Caixabank earlier this month.

The wider banking index rose 0.8% but is among the worst performing sectors this year alongside energy, as mounting bad loans due to the impact of the pandemic and record low interest rates hammered the appeal for the sector.

Travel and leisure stocks rose 0.9% as the rollout of COVID-19 vaccines across the continent took the edge off a surge in infection rates that is driving many countries to consider extending lockdowns.

Latest comments

you have to know what you want you have to grab it and ride it like a bull grad life like a bull and ride it
Plucking for hope, again and again
Record markets should be indicative of record prosperity, disposable income, peace, mutual trade deals, competent leaders (rather than mouth-pieces), record employment...all these things existed before China virus....NONE exist now. Going to be worse than 29’ before Biden is out of office...
good article
Ahh more vaccine "hope" you'd think on the third vaccine the forward looking markets would have priced it in already
Nope, has nothing to do with one vaccine. Boomer article
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.